Novo Nordisk, a long held position within the model portfolio, today announced phase 2 test results on its new oral diabetes medication. http://news.investors.com/022015-740166-novo-nordisk-lauds-phase-two-trial-for-diabetes-drug.htm?ven=yahoocp&src=aurlled&ven=yahoo There are potential breakthrough implications that one can glean from this result. Until now, the newest and…